OncoMatch/Clinical Trials/NCT05726383
Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
Is NCT05726383 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Iscador*P for osteogenic sarcoma recurrent.
Treatment: Iscador*P — This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid tumors and precancerous lesions. The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following completion of final thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with surveillance imaging via CT scan to monitor for relapsed disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Osteosarcoma
Sarcoma
Disease stage
Metastatic disease required
Prior therapy
Must have received: surgical resection — all gross metastatic disease
Surgical resection of all possible sites of suspected pulmonary metastases in order to achieve a complete remission within 8 weeks prior to study enrollment
Cannot have received: systemic chemotherapy
Patients must have had no systemic chemotherapy or immunotherapy in the three weeks prior to enrollment
Cannot have received: immunotherapy
Patients must have had no systemic chemotherapy or immunotherapy in the three weeks prior to enrollment
Cannot have received: radiation therapy
Patients must not have received radiation therapy for up to two weeks prior to enrollment
Cannot have received: chemotherapeutic agent (conventional or experimental)
Patients may not receive any additional chemotherapeutic agent (either conventional or experimental) while on study
Lab requirements
Blood counts
Absolute neutrophil count ≥ 500/dL; Platelet count ≥ 20,000/L
Kidney function
Creatinine ≤ 1.5x ULN or calculated creatinine clearance (CrCl) ≥ 60 ml/minute
Liver function
AST and ALT ≤ 5x ULN; total bilirubin < 2.5x ULN or direct bilirubin ≤ ULN for patients with total bilirubin > 2.5x ULN
Adequate hepatic function with serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal (ULN) and total serum bilirubin < 2.5 times the ULN or Direct bilirubin ≤ ULN for patients with total bilirubin levels > 2.5 X ULN; Absolute neutrophil count ≥ 500/dL; Platelet count ≥ 20,000/L; Creatinine ≤ 1.5 X the ULN or measurement of calculated creatinine clearance (CrCl) ≥ 60 ml/minute
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hackensack University Medical Center · Hackensack, New Jersey
- M.D. Anderson Children's Cancer Hospital · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify